Transformed B-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Transformed B-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy [Phase 2]
Phase 2 clinical trial evaluating a CD3xCD20 bispecific antibody for relapse/refractory B-cell non-Hodgkin lymphomas after CAR-T therapy has…
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma [Phase 2]
Phase 2 trial update on zanubrutinib combined with CAR T-cell therapy for recurrent or refractory aggressive B-cell non-Hodgkin lymphomas an…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse [Phase 2]
Phase 2 trial evaluating Golcadomide after CAR T-cell therapy in adults with relapsed/refractory aggressive diffuse large B-cell lymphoma an…
-
CLINICAL_TRIALS trial_result · 2024-08-26Clinical Trial Update: Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
Phase 2 study evaluating PolaR-ICE (polatuzumab vedotin, rituximab, ifosfamide, carboplatin, etoposide) as initial salvage therapy for relap…
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating mogamulizumab in combination with pembrolizumab for relapsed or refractory diffuse large B-cell lymphoma and rela…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.